87 related articles for article (PubMed ID: 28663057)
1. Inhibition of Mcl-1 enhances Pevonedistat-triggered apoptosis in osteosarcoma cells.
Zhang Y; Shi C; Yin L; Zhou W; Wang H; Seng J; Li W
Exp Cell Res; 2017 Sep; 358(2):234-241. PubMed ID: 28663057
[TBL] [Abstract][Full Text] [Related]
2. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
[TBL] [Abstract][Full Text] [Related]
3. Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma.
Wang J; Wang S; Zhang W; Wang X; Liu X; Liu L; Li L; Liang Y; Yu J; Jeong LS; Jia L; Zhao H; Zhang Y
Biochem Biophys Res Commun; 2017 Sep; 490(4):1183-1188. PubMed ID: 28669728
[TBL] [Abstract][Full Text] [Related]
4. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
[TBL] [Abstract][Full Text] [Related]
5. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.
Knorr KL; Schneider PA; Meng XW; Dai H; Smith BD; Hess AD; Karp JE; Kaufmann SH
Cell Death Differ; 2015 Dec; 22(12):2133-42. PubMed ID: 26045051
[TBL] [Abstract][Full Text] [Related]
6. The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.
Leclerc GM; Zheng S; Leclerc GJ; DeSalvo J; Swords RT; Barredo JC
Leuk Res; 2016 Nov; 50():1-10. PubMed ID: 27626202
[TBL] [Abstract][Full Text] [Related]
7. NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.
Liu X; Jiang Y; Wu J; Zhang W; Liang Y; Jia L; Yu J; Jeong LS; Li L
Biochem Biophys Res Commun; 2017 Jun; 488(1):1-5. PubMed ID: 28450112
[TBL] [Abstract][Full Text] [Related]
8. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.
Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A
Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900
[TBL] [Abstract][Full Text] [Related]
9. The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.
Zhang W; Liang Y; Li L; Wang X; Yan Z; Dong C; Zeng MS; Zhong Q; Liu XK; Yu J; Sun S; Liu X; Kang J; Zhao H; Jeong LS; Zhang Y; Jia L
Cell Prolif; 2019 Mar; 52(2):e12536. PubMed ID: 30341788
[TBL] [Abstract][Full Text] [Related]
10. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
11. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
[TBL] [Abstract][Full Text] [Related]
12. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.
Picco G; Petti C; Sassi F; Grillone K; Migliardi G; Rossi T; Isella C; Di Nicolantonio F; Sarotto I; Sapino A; Bardelli A; Trusolino L; Bertotti A; Medico E
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27771609
[TBL] [Abstract][Full Text] [Related]
14. Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.
Paiva C; Godbersen JC; Rowland T; Danilova OV; Danes C; Berger A; Danilov AV
Oncotarget; 2017 Mar; 8(13):21128-21139. PubMed ID: 28177892
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Myeloid Cell Leukemia 1 and Activation of Caspases Are Critically Involved in Gallotannin-induced Apoptosis in Prostate Cancer Cells.
Park E; Kwon HY; Jung JH; Jung DB; Jeong A; Cheon J; Kim B; Kim SH
Phytother Res; 2015 Aug; 29(8):1225-36. PubMed ID: 26014377
[TBL] [Abstract][Full Text] [Related]
16. Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1.
Li G; Zhang S; Fang H; Yan B; Zhao Y; Feng L; Ma X; Ye X
Biochem Biophys Res Commun; 2013 May; 434(4):809-14. PubMed ID: 23611778
[TBL] [Abstract][Full Text] [Related]
17. An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924).
Sumi H; Inazuka M; Morimoto M; Hibino R; Hashimoto K; Ishikawa T; Kuida K; Smith PG; Yoshida S; Yabuki M
Biochem Biophys Res Commun; 2016 Nov; 480(3):380-386. PubMed ID: 27771247
[TBL] [Abstract][Full Text] [Related]
18. Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis.
Zhang Y; Zhu X; Hou K; Zhao J; Han Z; Zhang X
Oncol Rep; 2015 May; 33(5):2277-84. PubMed ID: 25812695
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer.
Chen P; Hu T; Liang Y; Jiang Y; Pan Y; Li C; Zhang P; Wei D; Li P; Jeong LS; Chu Y; Qi H; Yang M; Hoffman RM; Dong Z; Jia L
Oncotarget; 2015 Apr; 6(11):9002-17. PubMed ID: 25797246
[TBL] [Abstract][Full Text] [Related]
20. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
Fan F; Tonon G; Bashari MH; Vallet S; Antonini E; Goldschmidt H; Schulze-Bergkamen H; Opferman JT; Sattler M; Anderson KC; Jäger D; Podar K
Cancer Lett; 2014 Feb; 343(2):286-94. PubMed ID: 24120758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
